JOP20220025A1 - المواد والطرق الخاصة باستهداف مستقبلات الأجسام المضادة البوليميرية - Google Patents
المواد والطرق الخاصة باستهداف مستقبلات الأجسام المضادة البوليميريةInfo
- Publication number
- JOP20220025A1 JOP20220025A1 JOP/2022/0025A JOP20220025A JOP20220025A1 JO P20220025 A1 JOP20220025 A1 JO P20220025A1 JO P20220025 A JOP20220025 A JO P20220025A JO P20220025 A1 JOP20220025 A1 JO P20220025A1
- Authority
- JO
- Jordan
- Prior art keywords
- plgr
- materials
- methods
- receptor targeting
- antibody receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
يصف هذا الكشف مجالات VHH التي ترتبط بمستقبل pIgR. وربما يتنافس مجالات VHH مع ارتباط IgA بمستقبل pIgR، أو بدلاً من ذلك، ربما يتنافس مجال VHH مع ارتباط IgA بمستقبل pIgR. ويمكن اقتران مجالات VHH بالعوامل العلاجية لتسهيل إعطاء العامل العلاجي إلى الطبقة المخاطية عبر التحول الخلوي بوساطة PIgR. وربما يكون العامل العلاجي عبارة عن جزيء صغير، أو جزيء كبير، أو حتى جسم مضاد.
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962882387P | 2019-08-02 | 2019-08-02 | |
US201962882346P | 2019-08-02 | 2019-08-02 | |
US201962882291P | 2019-08-02 | 2019-08-02 | |
US201962882361P | 2019-08-02 | 2019-08-02 | |
US201962940208P | 2019-11-25 | 2019-11-25 | |
US201962940196P | 2019-11-25 | 2019-11-25 | |
US201962940206P | 2019-11-25 | 2019-11-25 | |
US201962940228P | 2019-11-25 | 2019-11-25 | |
US201962940220P | 2019-11-25 | 2019-11-25 | |
US201962940200P | 2019-11-25 | 2019-11-25 | |
US201962940232P | 2019-11-25 | 2019-11-25 | |
PCT/US2020/044505 WO2021026000A1 (en) | 2019-08-02 | 2020-07-31 | Materials and methods for polymeric antibody receptor targeting |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20220025A1 true JOP20220025A1 (ar) | 2023-01-30 |
Family
ID=74502941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2022/0025A JOP20220025A1 (ar) | 2019-08-02 | 2020-07-31 | المواد والطرق الخاصة باستهداف مستقبلات الأجسام المضادة البوليميرية |
Country Status (18)
Country | Link |
---|---|
US (2) | US20230019640A1 (ar) |
EP (2) | EP4007607A4 (ar) |
JP (2) | JP2022542391A (ar) |
KR (2) | KR20220054585A (ar) |
CN (2) | CN114173801A (ar) |
AU (2) | AU2020326589A1 (ar) |
BR (2) | BR112022001352A2 (ar) |
CA (2) | CA3147916A1 (ar) |
CO (2) | CO2022000817A2 (ar) |
CR (2) | CR20220042A (ar) |
DO (2) | DOP2022000022A (ar) |
EC (2) | ECSP22007690A (ar) |
IL (2) | IL289955A (ar) |
JO (1) | JOP20220025A1 (ar) |
MX (2) | MX2022001278A (ar) |
PE (2) | PE20220298A1 (ar) |
TW (2) | TW202122108A (ar) |
WO (2) | WO2021026000A1 (ar) |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU728587B2 (en) * | 1996-06-04 | 2001-01-11 | Regents Of The University Of California, The | Cellular internalization of pIgR stalk and associated ligands |
US6060082A (en) * | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
WO2000047611A2 (en) * | 1999-02-12 | 2000-08-17 | Oklahoma Medical Research Foundation | Polymeric immunoglobulin receptor (pigr)-binding domains and methods of use therefor |
EP1268555A2 (en) * | 2000-03-27 | 2003-01-02 | The Regents of The University of California | Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof |
MXPA03002918A (es) * | 2000-10-02 | 2004-04-20 | Arizeke Pharmaceuticals Inc | Composiciones y metodos para el transporte de agentes biologicamente activos a traves de barreras celulares. |
US20030166160A1 (en) * | 2001-09-06 | 2003-09-04 | Hawley Stephen B. | Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands |
AU2002305140A1 (en) * | 2001-04-03 | 2002-10-28 | Arizeke Pharmaceuticals, Inc. | Compositions and methods for transepithelial transport of membrane-bounded vesicles and virions |
AU2004204763A1 (en) * | 2003-01-09 | 2004-07-29 | Arizeke Pharmaceuticals Inc. | Compositions and methods for targeted biological delivery of molecular carriers |
EP2101801A1 (en) * | 2006-12-20 | 2009-09-23 | Ablynx N.V. | Oral delivery of polypeptides |
US20100166734A1 (en) * | 2006-12-20 | 2010-07-01 | Edward Dolk | Oral delivery of polypeptides |
EP1975178A1 (en) * | 2007-03-30 | 2008-10-01 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Transcytotic modular antibody |
WO2009080764A2 (en) * | 2007-12-20 | 2009-07-02 | Abylnx N.V. | Oral or nasal administration of compounds comprising amino acid sequences |
EP2753644A1 (en) * | 2011-09-09 | 2014-07-16 | Universiteit Utrecht Holding B.V. | Broadly neutralizing vhh against hiv-1 |
AU2013201422B2 (en) * | 2012-01-23 | 2015-04-09 | Ablynx Nv | Sequences directed against hepatocyte growth factor (HFG) and polypeptides comprising the same for the treatment of cancers and/or tumors |
EP2917731B1 (en) * | 2012-11-08 | 2019-12-25 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Diagnostic, prognostic, therapeutic and screening protocols |
WO2017172517A1 (en) * | 2016-03-29 | 2017-10-05 | Stcube & Co., Inc. | Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins |
WO2018222506A1 (en) * | 2017-05-27 | 2018-12-06 | Immune-Onc Therapeutics, Inc. | Modulation of immunoglobulin-a-positive cells |
-
2020
- 2020-07-31 EP EP20850058.7A patent/EP4007607A4/en active Pending
- 2020-07-31 MX MX2022001278A patent/MX2022001278A/es unknown
- 2020-07-31 TW TW109126108A patent/TW202122108A/zh unknown
- 2020-07-31 BR BR112022001352A patent/BR112022001352A2/pt not_active Application Discontinuation
- 2020-07-31 JO JOP/2022/0025A patent/JOP20220025A1/ar unknown
- 2020-07-31 CR CR20220042A patent/CR20220042A/es unknown
- 2020-07-31 PE PE2022000180A patent/PE20220298A1/es unknown
- 2020-07-31 CA CA3147916A patent/CA3147916A1/en not_active Abandoned
- 2020-07-31 AU AU2020326589A patent/AU2020326589A1/en active Pending
- 2020-07-31 JP JP2022506123A patent/JP2022542391A/ja active Pending
- 2020-07-31 WO PCT/US2020/044505 patent/WO2021026000A1/en active Application Filing
- 2020-07-31 KR KR1020227003638A patent/KR20220054585A/ko unknown
- 2020-07-31 CN CN202080055485.8A patent/CN114173801A/zh active Pending
- 2020-07-31 TW TW109126094A patent/TW202116813A/zh unknown
- 2020-07-31 PE PE2022000168A patent/PE20220344A1/es unknown
- 2020-07-31 CR CR20220043A patent/CR20220043A/es unknown
- 2020-07-31 CN CN202080061126.3A patent/CN114423451A/zh active Pending
- 2020-07-31 KR KR1020227003585A patent/KR20220054289A/ko unknown
- 2020-07-31 WO PCT/US2020/044497 patent/WO2021025997A1/en active Application Filing
- 2020-07-31 CA CA3147905A patent/CA3147905A1/en not_active Abandoned
- 2020-07-31 US US17/630,706 patent/US20230019640A1/en active Pending
- 2020-07-31 BR BR112022001080A patent/BR112022001080A2/pt not_active Application Discontinuation
- 2020-07-31 US US17/630,718 patent/US20220324970A1/en active Pending
- 2020-07-31 JP JP2022506274A patent/JP2022542418A/ja active Pending
- 2020-07-31 EP EP20849929.3A patent/EP4007591A4/en active Pending
- 2020-07-31 MX MX2022001379A patent/MX2022001379A/es unknown
- 2020-07-31 AU AU2020326590A patent/AU2020326590A1/en active Pending
-
2022
- 2022-01-18 IL IL289955A patent/IL289955A/en unknown
- 2022-01-18 IL IL289956A patent/IL289956A/en unknown
- 2022-01-28 DO DO2022000022A patent/DOP2022000022A/es unknown
- 2022-01-28 DO DO2022000021A patent/DOP2022000021A/es unknown
- 2022-01-28 CO CONC2022/0000817A patent/CO2022000817A2/es unknown
- 2022-01-31 EC ECSENADI20227690A patent/ECSP22007690A/es unknown
- 2022-02-16 CO CONC2022/0001579A patent/CO2022001579A2/es unknown
- 2022-02-24 EC ECSENADI202214913A patent/ECSP22014913A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019013033A (es) | Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
MX2020006408A (es) | Moléculas de unión al antígeno biespecíficas. | |
WO2016164731A8 (en) | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell | |
WO2020037150A3 (en) | Engineered bispecific proteins | |
MY171007A (en) | Bispecific binding molecules binding to vegf and ang2 | |
WO2010002862A3 (en) | Fibroblast growth factor receptor 3 (fgfr3) binding proteins | |
GEP20115226B (en) | P-cadherin antibodies | |
MA32888B1 (ar) | أجسام مضادة ل igf | |
WO2020082209A8 (zh) | 抗cldn18.2抗体及其用途 | |
AU2010310545A8 (en) | Anti-GCC antibody molecules and related compositions and methods | |
EA201200548A1 (ru) | Биспецифические связывающие молекулы для антиангиогенезной терапии | |
MX2012012927A (es) | Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6). | |
WO2015108998A8 (en) | Cartilage targeting agents and their use | |
WO2015069922A3 (en) | Alk antibodies, conjugates, and chimeric antigen receptors, and their use | |
EA201691780A1 (ru) | Наноструктурированный песок, способ получения наноструктурированного песка, способ разделения смеси загрязняющее вещество-вода с помощью наноструктурированного песка и дополнительные применения | |
MX2021011750A (es) | Anticuerpos anti-egfrviii y fragmentos de union a antigenos de los mismos. | |
UA120048C2 (uk) | Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r) | |
WO2012009631A8 (en) | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods | |
EA201691782A1 (ru) | Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения | |
WO2009132081A3 (en) | Monoclonal antibody-based targeting of folate receptors | |
NZ740474A (en) | Antigen receptors and uses thereof | |
WO2019168947A8 (en) | Bifunctional proteins combining checkpoint blockade for targeted therapy | |
MX2016006301A (es) | Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos. | |
WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
MX2017009680A (es) | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). |